Strategic Partnerships Position Bloom Science as a partner for neurology-focused biotech funds, pharma companies, and patient advocacy organizations seeking innovative gut-brain axis therapies, highlighting their CNS pipeline and live biotherapeutic approach to unlock new therapeutic modalities.

Clinical Stage Opportunities Leverage Bloom’s clinical-stage status and programs in Dravet syndrome, rare epilepsies, ALS, and neurodegenerative disorders to target research collaborations, co-development deals, and milestone-based funding with risk-sharing models.

Strategic Investor Engagement Engage investors active in neuroscience and biotech with Bloom’s leadership participation at major conferences, emphasizing the IrisRx platform, gut-brain axis biology, and safety advantages to attract early-stage to specialty biotech capital.

Manufacturing & Scale Offer discussions around scalable GMP manufacturing and supply chain readiness for live biotherapeutic products to potential manufacturing-focused partners, contract development and manufacturing organizations (CDMOs), and strategic allies.

Data & IP Collaboration Propose joint data-sharing, biomarker validation, and synthetic biology collaboration opportunities using Bloom’s expanding proprietary knowledge base to de-risk programs and accelerate candidates through regulatory milestones.